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Abstract
Challenges today concern chronic myeloid leukemia (CML) patients resistant to imatinib. There is growing evidence that
imatinib-resistant leukemic cells present abnormal glucose metabolism but the impact on mitochondria has been
neglected. Our work aimed to better understand and exploit the metabolic alterations of imatinib-resistant leukemic cells.
Imatinib-resistant cells presented high glycolysis as compared to sensitive cells. Consistently, expression of key glycolytic
enzymes, at least partly mediated by HIF-1a, was modified in imatinib-resistant cells suggesting that imatinib-resistant cells
uncouple glycolytic flux from pyruvate oxidation. Interestingly, mitochondria of imatinib-resistant cells exhibited
accumulation of TCA cycle intermediates, increased NADH and low oxygen consumption. These mitochondrial alterations
due to the partial failure of ETC were further confirmed in leukemic cells isolated from some imatinib-resistant CML patients.
As a consequence, mitochondria generated more ROS than those of imatinib-sensitive cells. This, in turn, resulted in
increased death of imatinib-resistant leukemic cells following in vitro or in vivo treatment with the pro-oxidants, PEITC and
Trisenox, in a syngeneic mouse tumor model. Conversely, inhibition of glycolysis caused derepression of respiration leading
to lower cellular ROS. In conclusion, these findings indicate that imatinib-resistant leukemic cells have an unexpected
mitochondrial dysfunction that could be exploited for selective therapeutic intervention.
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Introduction
Chronic myeloid leukaemia (CML) is provoked by the BCR-
ABL translocation which leads to clonal myeloid cell expansion.
The tyrosine kinase Bcr-Abl activates many intracellular signalling
cascades conferring clear advantages for cancer cells. The
apparition of the first competitive inhibitor of the Bcr-Abl tyrosine
kinase, imatinib (Gleevec) in 2001 has revolutionized the prognosis
of CML. In an attempt to improve the outcome of CML patients,
second generation tyrosine kinase inhibitors (TKI) including
dasatinib have been developed [1]. Unfortunately, development
of resistance to imatinib is frequent and up to 28% of patients may
have to stop imatinib because of secondary resistance. In addition,
blasts from transformed CML are also mostly chemo-resistant,
leaving no treatment option. Several mechanisms can explain the
loss of imatinib sensitivity. Emergence of mutations within the
ATP pocket of the Bcr-Abl kinase domain providing constitutive
kinase activity plays an important role in imatinib resistance [2]. In
humans, the most prevalent mutation E255K confers resistance to
imatinib only, while others like T315I lead to multiple resistances
including second-generation TKI [3]. However, imatinib resis-
tance in CML is not necessarily caused by BCR-ABL mutations
and CML patients who escape to imatinib therapy frequently
express a non mutated form of BCR-ABL [4].
Therefore studies aimed to develop innovative strategies to
overcome imatinib resistance and to eradicate CML are needed.
Recently, the metabolic profile of Bcr-Abl (+) cells has attracted
widespread interest. Activation of the PI3-kinase/Akt/mTOR
pathway by Bcr-Abl contributes to the high glycolytic activity
observed in Bcr-Abl positive cells [5,6]. Expression of the Bcr-Abl
kinase in haematopoietic cells stimulates increase in glucose uptake
[7] through a PI3-kinase-dependent translocation of glucose
transporters to the plasma membrane [8]. Besides, the constitutive
activity of the serine/threonine kinase Akt has been shown to
increase glucose consumption and lactate production in many
cancer cells [9].
Imatinib, which causes the inhibition of the Bcr-Abl signalling
cascade, controls the glucose flux by inhibition of the subcellular
redistribution of the glucose transporter, GLUT1 [5] and also
markedly affects metabolic organization of Bcr-Abl positive cells
[6,10]. At clinically relevant concentrations, imatinib strongly
suppresses cytosolic glycolysis then increases the TCA cycle
intermediates evoking a compensatory activation of mitochondrial
function [10,11]. In contrast, imatinib-resistant cells maintain
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suggesting that increased glucose metabolism participates to
imatinib resistance.
Additionally, Bcr-Abl expressing cells harbour high levels of
intracellular reactive oxygen species (ROS) and it has been
speculated that increased glucose metabolism in these cells leads to
ROS overproduction [13]. In Bcr-Abl expressing cells, mitochon-
dria are a relevant source of ROS [13]. However, ROS derived
from NADPH oxidase 4 also play a role in survival signalling in
CML [14]. Inhibition of the antioxidant system with PEITC leads
to further increase in ROS levels resulting in selective cell death of
Bcr-Abl positive cells [15,16]. Interestingly, PEITC can also
promote ROS-mediated death of imatinib-resistant leukemia cells
[16].
Since mitochondria are at the center for bioenergetics
metabolism and ROS generation, we investigated the regulation
of energy metabolism in imatinib-sensitive and -resistant leukemic
cells focusing on mitochondrial functions. In this report, we
provided a comprehensive analysis of the changes observed in the
structure and function of mitochondria that occur in imatinib-
resistant leukemic cells and demonstrated that exploiting the
differential metabolic phenotype of imatinib-resistant cells presents
opportunities for therapeutic action.
Materials and Methods
Chemicals
All chemicals were purchased from Sigma-Aldrich (St Louis,
MO, USA) except 5,59 ,6,69 -tetrachloro-1,19 ,3,39 -tetraethylben-
zimidazolyl- carbocyanine iodide (JC-1), MitoTrackerGreen
(MTG) and Mitosox Red from Molecular Probes (Eugene, OR,
USA).
Cell culture conditions
From the murine DA1-3b cell line generated by stable
transfection of bcr-abl [17], we established the clone DA1-3b/
M2 by adding increasing concentrations of imatinib and dasatinib
to the culture medium [18]. Acquired resistance of DA1-3b/M2 is
mediated by composite T315I and E255K BCR-ABL mutations
[18]. DA1-3b and DA1-3b/M2 were grown at 37uC under 5%
CO2 in DMEM medium (Gibco-BRL, Life Technologies SARL,
Cergy-Pontoise, France) containing 25 mM glucose supplemented
with 10% fetal calf serum (Gibco-BRL), 50 U/ml penicillin,
50 mg/ml streptomycin, and 1 mM sodium pyruvate (Gibco-
BRL). For siRNA inhibition of HIF-1a, DA1-3b/M2 cells were
either transfected with 100 nM SiRNA HIF-1a (sc-35562, Santa
Cruz Biotechnology Inc., Heidelberg, Germany) or 100 nM
control non-targeting SiRNA (sc-37007) using lipofectamine
2000 (Life Technologies, Gaithersburg, MD, USA) according to
the manufacturer’s protocol. The CML-derived K562 cell line and
its resistant derived sublines, K562-NI (resistant to nilotinib and
imatinib), and K562-IM with acquired imatinib resistance) (kindly
provided by Pr Franc ¸ois-Xavier Mahon, CHU Bordeaux, France)
were cultured in DMEM medium. K-562-IM and K-562-NI were
characterized by the absence of mutation in the BCR-ABL kinase
domain [19,20]. Bone marrow samples were obtained from 4
CML patients resistant to imatinib. Normal CD34+ cells were
obtained from bone marrow aspirates from healthy donors that
gave informed consent in accordance with the Declaration of
Helsinki. For in vivo experiments, DA1-3b/M2 cells were
transfected with eGFP on the pVITRO plasmid (InvivoGen,
California, USA) using the Amaxa Nucleofactor device (Amaxa,
Ko ¨ln, Germany), with a Cell Line specific Nucleofector kit V
(program O17) according to the manufacturer’s instructions. After
48 h, cells were selected in medium containing Blasticidin at
20 mg/ml (InvivoGen) for up to 12 days.
Ethics Statement
Informed signed consent for cell analysis was obtained from
each patient and donor included and the study was approved by
our institutional ethical committee (CPP Lille). All animal
experiments were performed as approved by the Animal Care
Ethical Committee CEEA.NPDC (Agreement # AF-03-2008).
Glucose and lactate measurements
Glucose and lactate were measured in the extracellular medium
using a SYNCHRON LX20 Clinical system (Beckman Coulter,
Fullerton, CA USA).
Cytofluorometric analysis
The selective detection of superoxide in the mitochondria of
cancer cells was determined using the MitoSox Red probe
following current protocols [21] and analyzed on a FACS Canto
cytofluorometer equipped with the FACS-Diva research software
(Beckton Dickinson). The inner mitochondrial transmembrane
potential (DYm), was determined with JC-1 [22]. Results were the
ratio between the fluorescence of sample cells and the fluorescence
obtained after incubation of cells with the mitochondrial
uncoupler, ClCCP. For mitochondrial mass, cells were incubated
with 50 nM MTG as described [22]. Assessment of cell death was
performed using the protocol outlined in the FITC-Annexin kit
(BD Pharmingen, San Diego, CA, USA).
Real-time Quantitative RT-PCR
Total RNAs were isolated using the RNAzol B method (WAK-
Chemie Medical GmBH, Germany) according to manufacturer’s
instructions. cDNAs were synthesized with the High Capacity
Transcription Kit (Applied Biosystems, CA, USA) from 1 mgo f
total RNA. For a list of primers, see Material and Methods S1.
Real-time PCR was performed with the cDNA samples and
Express SYBR green ER Supermixes (Invitrogen, Carlsbad, CA,
USA) using a cycling protocol optimized for Lightcycler 480
detector (Roche Applied Science, Manheim Germany) as we
described elsewhere [23]. All samples were amplified in triplicates.
The transcripts level in each sample was normalized to that of 18S
rRNA. The relative expression of target mRNAs in DA1-3b/M2
cells was compared with the expression in DA1-3b using the Pfafll
method with a fold change criteria of 1.5 [24].
NMR analysis
The frozen cell pellet (15610
6 cells) was extracted according to
Beckonert’s procedure [25] with CHCl3/MeOH/H2O (2:2:1.425
(v/v/v)). The lyophilisate was dissolved in 550 mL of D2O
(Eurisotop, France) and 5 mL of a 5 mM solution of TSP (sodium
2,2,3,3-tetradeutero-3-trimethylsilylpropionate) (Sigma-Aldrich)
were added as internal chemical shift and quantification reference.
1H NMR spectra were recorded on a Bruker Avance spectrom-
eter. All 1H experiments were acquired at 298K using a classical
1D pulse sequence (relaxation delay-pulse-acquisition) with a 2.0 s
pre-saturation pulse for water suppression and a repetition time of
6.1 s. A flip angle of 30u was employed with 32K data points for
acquisition over a spectral width of 10 ppm, and 1024 scans were
collected. Data were processed using Bruker TopSpin software 2.1
with one level of zero-filling, and Fourier transformation after
multiplying FIDs by an exponential line-broadening function of
0.3 Hz. The concentrations of metabolites were calculated by
comparing the expanded areas of their respective NMR signals
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areas were determined by automatic integration using the
KnowItAllH software.
Immunoblot analysis
Cells (3610
6 for each sample) were resuspended in extraction
buffer and lysates were prepared as described previously [26]. For
analysis of OXPHOS complexes, 25 mg proteins were separated
on a 4–12% SDS-PAGE denaturing gel and transferred to
nitrocellulose membrane (Amersham BioSciences, Piscataway,
NJ). Equivalent loading was checked by actin staining. Membranes
were blocked in 5% milk in TBST buffer then probed with a
premixed cocktail of five monoclonal antibodies (total OXPHOS
antibody cocktail kit, MitoSciences, 1:200) specifically recognizing
CI subunit NDUFB8 (MS105), CII-30 kDa (MS203), CIII-Core
protein 2 (MS304) CIV subunit I (MS404) and CV alpha subunit
(MS507). For analysis of glycolysis-related proteins, 20 mg proteins
were subjected to SDS-PAGE. Membranes were blocked in 10%
powdered milk in TBS Tween 0.05% for 1 h at room temperature
and then incubated with primary antibodies specific for SLC2A1
(1:200, Santa Cruz, H-43), SLC2A6 (1:500, Santa Cruz, M-16),
Pdk3 (1:500, Santa Cruz, RR-21), Lamin A/C(1:200, Santa Cruz,
636), Hk2 (1:500, Cell Signaling, C64G5), Pfkp (1:200, Cell
Signaling), AldoA (1:200, Cell Signaling). Secondary horseradish
peroxidase–conjugated antibodies (BioRAD) were used at 1:2,000
for 1 h at room temperature, and detection was carried out by
enhanced chemiluminescence. Anti-actin Ab (1:5,000, Sigma) was
used for standardization of protein loading. For HIF-1a, nuclear
fractions (30 mg), prepared with a commercial kit (nuclear
fractionation kit from BioVision), were analyzed using anti- HIF-
1a monoclonal Ab (1:500, Santa Cruz, H-206). Anti lamin A/C
Ab (1:200, Santa Cruz, 636) was used to check for equal loading.
Pyridine nucleotide and ATP measurements
We analyzed the pyridine nucleotides (NAD+/NADH ratio) in
whole cell lysates and the level of NADH in mitochondria isolated
from cells with the NAD
+/NADH Quantification assay kit
according to manufacturer’s instructions (BioVision, Mountain
View, CA). For ATP determination, the Celltiter Glow Assay kit
(Promega) was used according to the manufacturer’s procedures.
Measurement of oxygen consumption
Cells were suspended at 2610
6 cells/ml in cell culture medium.
Oxygen consumption was monitored over time with a polaro-
graphic oxygen electrode (Oxygraph-2k, Oroboros Instruments,
Innsbruck, Austria) as described [27]. Cell viability was assessed by
propidium iodide staining at the end of this experiment. In
respiration studies using non-permeable substrates of respiratory
chain, cells were permeabilized with digitonine (50 mg/ml final
concentration) in the oxygraph chamber.
Analysis of mitochondrial respiratory chain complex
enzyme activities
Mitochondria were purified from cells following standard
protocols [26]. Isolated mitochondria (1 mg/ml) were suspended
in buffer containing 75 mM saccharose, 225 mM mannitol,
0.1 mM EDTA and 10 mM Tris-HCl, pH 7.2 and incubated
on ice. Samples were incubated at 37uC for 15 minutes. Enzyme
activities were immediately assayed at 30uC spectrophotometri-
cally using a SAFAS UVMc2 spectrophotometer (Safas Monaco)
following standard procedures [28].
NADPH oxidase assay
NADPH oxidase activity was measured in membrane fractions
by lucigenin chemiluminescence. 5 mg of proteins were incubated
with 50 mM lucigenin in HBSS 16. The reaction was started by
adding 100 mM NADPH then relative light units (RLU) of
chemiluminescence were read in a 96-well luminometer (Mithras,
LB940, Berthold Technologies, Thoiry, France). Photon emission
was measured every 15 s for the initial 5 min corresponding to the
linear portion of luminescence generation. The background
chemiluminescence of the buffer was always subtracted from each
reading before data calculations. There was no measurable activity
in the absence of NADPH.
Transmission electron microscopy
Cells were prepared for transmission electron microscopy as
described previously [22] .
In vivo study
Seven to 8-week-old C3H/HeOUJ female mice (Charles River
Laboratories) were injected i.p. with 1610
6 GFP-transfected DA-
13b/M2 cells. Treatment started 24 h after cell inoculation with
i.p. injection of vehicle, Trisenox (As2O3; 4 mg/kg five times a
week) or PEITC (PhenylEthyl IsothioCyanate); 50 mg/kg five
times a week. Drug injections were terminated after one month
and mice were monitored daily for signs of tumor growth and
shaggy hair. Moribund animals were sacrificed and spleens were
removed. Residual M2-GFP cells were immediately analyzed by
flow cytometry for viability and ROS production.
Figure 1. Characterization of glucose metabolism in imatinib-sensitive and -resistant cells. (A) DA1-3b (imatimib-sensitive) and DA1-3b/
M2 (imatinib-resistant) leukemic cells were cultured in DMEM (containing 25 mM of glucose) (%) or in medium containing 1 mM glucose and 10 mM
2-Deoxyglucose (2-DG) (&) for 18 h, then treated with 1 mg/ml oligomycin or 1 mM rotenone for 4 h. Cells were then collected for total ATP
measurement as described in Materials and Methods. Data shown are means +/2 SD of four separate cell preparations. (B) Exponentially growing
DA1-3b and DA1-3b/M2 cells were resuspended in fresh DMEM medium at a density of 2610
6 cells/ml. At indicated times, glucose (left) and lactate
(right) were measured in the supernatants. Data are means +/2 SD of three independent experiments (C) (left) Schematic overview of glucose
metabolism to point out the position of studied genes in metabolism. (middle) Quantitative PCR analysis of relative transcript levels of glucose
transporters, glycolytic enzymes and enzymes related to lactate metabolism in DA1-3b/M2 cells compared with DA1-3b cells. Data are means +/2 SD
of four independent experiments. (right) Immunoblot analysis of protein abundance in DA1-3b and DA1-3b/M2 cells. Densitometric values of
proteins are normalized on the basis of actin expression and expressed as fold induction in DA1-3b/M2 cells over DA1-3b cells (n=2). (D) (left)
Expression of HIF-1a protein in DA1-3b and DA1-3b/M2 cells. Nuclear extracts were analyzed by immunoblotting against HIF-1a. Lamin A/C was used
as a loading control. Alternatively, DA1-3b/M2 cells were treated with either HIF-1a siRNA or control non-targeting siRNA. Knock down of HIF-1a was
confirmed by immunoblot at 48 h post transfection. Data are representative of 3 different experiments. (middle). The effect of HIF-1a knock-down in
DA-13b/M2 cells on expression of glycolysis-related proteins. Protein expression was measured by immunoblot densitometry and normalized to
actin. The values in HIF-1a silenced DA1-3b/M2 cells are reported as the fold decrease over control (n=2). (right) Effects of loss of HIF-1a expression in
DA-13b/M2 cells on glucose utilization and lactate production. Exponentially growing DA1-3b/M2 cells transfected with siControl or si HIF-1a were
incubated in fresh DMEM medium at a density of 2610
6 cells/ml. At 24 h, glucose and lactate were measured in the supernatants. Data are means of
two independent experiments.
doi:10.1371/journal.pone.0021924.g001
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The student’s t-test was used to compare data sets using
GraphPad PrismH version 4.00 (GraphPad Software, San Diego,
CA, USA). Statistical significance was set at P,0.05. Kaplan-
Meier curve comparison was performed with the log-rank test.
Results
Glucose metabolism in imatinib-sensitive and imatinib-
resistant leukemic cells
We have previously established a cellular model to imitate the
process of imatinib resistance in patients [18]. From the parental
Bcr-Abl (+) leukemic cell line DA1-3b which is sensitive to tyrosine
kinase inhibitors, we have generated the imatinib and dasatinib
resistant cell line, DA1-3b/M2, carrying the most frequent Bcr-
Abl mutations (T315I and E255K) associated with resistance in
patients [18]. In normal culture with DMEM containing 25 mM
glucose, DA1-3b and DA1-3b/M2 cell lines had a similar ATP
content (0.640+/20.04 vs. 0.644+/20.10 nmol/10
6 cells; n=3).
Incubation of DA1-3b and DA1-3b/M2 cells in low glucose
medium with the inhibitor of glycolysis, 2-DG, yielded a drastic
depletion of more than 60% in cellular ATP level. By comparison,
suppression of the mitochondrial oxidative phosphorylation with
the respiratory inhibitor, rotenone or the phosphorylation
inhibitor oligomycin did not exert a major inhibitory effect on
cellular ATP production (Fig. 1A). Additionally, both cell lines
maintained, under normoxic conditions, avid glucose consumption
with concomitant high lactate production. When compared with
DA1-3b, DA1-3b/M2 cells were more active in glucose utilization
and produced more lactate (Fig. 1B). Consistently, we identified by
quantitative real-time PCR 7 genes involved in glycolysis which
were specifically up-regulated in DA1-3b/M2 cells. Glucose
transporter genes (SCL2A1, SCL2A6), genes (HKII, GPI, PFKP,
ALDOA) encoding enzymes involved in the first four steps of the
glycolysis were up-regulated in DA1-3b/M2 cells. Similarly, up-
regulation of LDHA was observed in DA1-3b/M2. In addition, we
assumed an impaired oxidative metabolism of pyruvate in DA1-
3b/M2 mitochondria since PDH expression was decreased with a
concomitant increase in PDK3 as compared to DA1-3b cells. In
line with qPCR results, the levels of some important glycolysis-
related proteins were up-regulated in DA1-3b/M2 cells as
determined by immunoblot (Fig. 1C). These experiments were
repeated using the human CML-derived K562 cell line and its
resistant derived sublines (K562-IM, K562-NI) with similar
outcomes (FigS1). Since HIF-1a is a master transcriptional
regulator of glucose metabolism in cancer cells, we investigated
the role of HIF-1a in glycolysis in imatinib-resistant cells. Under
normoxic condition, expression of HIF-1a was found elevated in
imatinib-resistant DA1-3b/M2 cells as compared to sensitive cells
(Fig. 1D, left). To determine whether HIF-1a could be
contributing to glycolysis in these cells, DA1-3b/M2 cells were
transfected with siRNA targeting HIF-1a which consistently
decreased its expression by ,75% (Fig. 1D, left). In these
conditions, expression of several glycolysis-related proteins was
decreased in HIF-1a siRNA transfected DA1-3b/M2 cells
compared to control cells (Fig. 1D, middle). Consistently, glucose
utilization and lactate production were also decreased in HIF-1a
silenced cells (Fig. 1D, right). Thus, imatinib-resistant leukemic
cells present increased glycolytic rate and shift to lactate
production as compared to their sensitive counterparts. The
highly glycolytic phenotype of imatinib-resistant leukemic cells was
partially dependent on HIF-1a activity.
Mitochondrial characteristics of imatinib-sensitive and
imatinib-resistant leukemic cells
Since imatinib-resistant cells present increased glycolysis, we
suspected that DA1-3b/M2 cells have defective mitochondria.
Transmission electron microscopy revealed that mitochondria in
DA1-3b/M2 cells were smaller, with less electron-dense matrix
(Fig. 2A and B), a feature already observed in leukemic cells with
mitochondrial defects [29]. There was no difference in mitochon-
drial mass as detected by MTG fluorescence (Fig. 2C) and no
difference in the number of mitochondria between DA1-3b and
DA1-3b/M2 cells (not shown). We observed that DA1-3b/M2
cells had a slight lower DYm than DA1-3b cells (Fig. 2C).
Interestingly, DA1-3b/M2 cells in culture medium exhibited a
significantly lower oxygen consumption rate than DA1-3b
(Fig. 2D). The decrease in oxygen consumption rates can be
explained by a decrease in ATP turnover (respiration coupled to
ATP synthesis) as well as a decrease in proton leak (uncoupled
respiration) (Fig. 2E). In a similar manner, mitochondrial
dysfunction was associated with imatinib resistance of human
CML K562 cells (Fig. S2). We found an increase in NADH/
NAD+ ratio and mitochondrial NADH concentration in DA1-3b/
M2 cells (Fig. 2F). Consistently, when we studied the tricarboxylic
acid (TCA) cycle that connects glucose metabolism to oxidative
phosphorylation, an accumulation of TCA intermediates (succi-
nate, fumarate and malate) and elevated level of glutamate, a
major respiratory substrate of cancer cells [30], were observed in
DA1-3b/M2 cells in comparison with DA1-3b (Fig. 2G). Thus,
accumulation of TCA intermediates, which correlated to NADH
increase, may indicate alterations of the electron transport chain
(ETC) in mitochondria of imatinib-resistant cells.
Figure 2. Characterization of mitochondrial alterations in imatinib-resistant cells. (A) Transmission electron microscopic images of DA1-3b
(imatimib-sensitive), DA1-3b/M2 (imatinib-resistant) cells. Typical representative morphologic features of cells (magnification, 67,000) and
mitochondria (magnification, 620,000); (B) Size of mitochondria per DA1-3b cells or DA1-3b/M2 cells. A total of 500 cells were examined in
transmission electronic microscopy and mitochondrial size were evaluated. Values are medians (horizontal bars) with 25–75% interquartile ranges
(boxes) and minimum–maximum values (I) (*P=0.02 between DA1-3b and DA1-3b/M2 cells); (C) (left) Representative flow cytometric measurement
of mitochondrial mass. DA1-3b and DA1-3b/M2 cells were labeled with the MTG fluorescent dye. (right) Flow cytometric measurement of DYm. DA1-
3b and DA1-3b/M2 cells were labeled with JC-1. JC-1 fluorescence (mean fluorescence intensity) ratio is normalized to that of depolarized cells (cells
incubated with 20 mM ClCCP used as a positive control for loss of DYm). Values are means 6 S.D of five measurements; (D) Comparison of oxygen
consumption in DA1-3b and DA1-3b/M2 cells. DA1-3b or DA1-3b/M2 cells (2610
6/ml) in DMEM were added to a closed chamber with an oxygen
electrode at 37uC and oxygen levels were monitored over time. Data are representative of five independent experiments; (E) Proportions of
mitochondrial oxygen consumption due to proton leak and ATP turnover reactions in DA1-3b and DA1-3b/M2 cells. Proton leak corresponds to the
respiration that is not modified by the inhibitor of the ATP synthase, oligomycin whereas ATP turnover constitutes the respiration that is inhibited by
oligomycin. Oxygen consumption was determined as in (D). Data are means +/2 SD of three separate experiments; (F) Determination of cytoplasmic
NADH/NAD ratio (left) and mitochondrial NADH in DA1-3b and DA1-3b/M2 cells. Data are means +/2 SD of three independent experiments in
triplicates; (G) Quantified levels of mitochondrial TCA cycle related metabolites in DA1-3b and DA1-3b/M2. Metabolites detected (black boxes) are
represented on a comprehensive metabolic pathway map. Results are means +/2 SD of fifteen
1H NMR spectra of the metabolome for each of the
individual cell cultures.
doi:10.1371/journal.pone.0021924.g002
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To analyze the loss of integrity of the ETC complexes, we
measured substrate-driven oxygen consumption in digitonin-
permeabilized cells (Fig. 3A). Compared with DA1-3b cells,
respiration in DA1-3b/M2 cells with complex I- (glutamate/
malate), or complex II-linked substrate (succinate), was signifi-
cantly reduced both during state 3 (in the presence of ADP) and
state 4 (without ADP). When we investigated electron flow post-
cytochrome c to complex IV by using TMPD/ascorbate and
antimycin A (to block complex III), DA1-3b/M2 showed a slightly
lower rate of oxygen consumption (Fig. 3A, left part). As with
murine cells, human imatinib-resistant cell lines, K562-IM and
K562-NI, displayed decreased substrate-dependent respiration
rate in comparison with imatinib sensitive K562 cells (Fig. 3A,
right part).
To confirm these results, we measured the activities of
respiratory enzymes in mitochondria isolated from both cell lines
(Fig. 3B–E). NADH dehydrogenase (complex I) showed the
highest reduction of activity in DA1-3b/M2 as compared with
DA1-3b cells (3-fold lower, p,0.01). Mitochondria isolated from
DA1-3b/M2 cell also displayed a significant reduction in the
activities of succinate ubiquinone reductase (Complex II; 2-fold
lower, p,0.05), and cytochrome c oxidase (Complex IV;
approximatively 1.5-fold lower, p,0.05). Quinol cytochrome c
reductase (QCCR, complex III) activity appeared much smaller in
DA1-3b/M2 but was not statistically significant. We next analyzed
components of mitochondrial ETC by Western blotting using a
cocktail of monoclonal antibodies optimized for the detection of
one subunit of each of the five complexes [31]. In further support
of a reduction in mitochondrial functions, proteins of complexes I
and II were significantly less abundant in DA1-3b/M2 cells than
in DA1-3b cells, complexes IV and V appeared less expressed in
DA1-3b/M2 cells but failed to reach statistical significance,
complex III remained similar in both cell lines (Fig. 3F). Reduction
in protein expression was correlated with the lower activities of
mitochondrial complexes found in DA1-3b/M2 (Fig. 3B–E)
suggesting that the corresponding complex failed to assemble
properly. DA1-3b/M2 cells, which were recovered ex vivo from
injected mice, retained the same expression of mitochondrial
complexes (not shown). Moreover, two additional imatinib-
resistant cell lines (K562-NI and K562-IM) had lower expression
of most of the ETC proteins compared with their sensitive
counterparts (K562) (Fig. 3F). In comparison with normal CD34 +
cells, no changes in ETC protein expression was found in CML
leukocytes isolated from patient with primary resistance to
imatinib (patient 1) or from patient with partial response (patient
2) (Fig. 3F and Table S1). Conversely, reduction in ETC protein
expression was evident in CML leukocytes isolated from two
imatinib-resistant patients in the accelerated/blastic phase of the
disease (patients 3 and 4, Fig. 3F and Table S1). Thus,
mitochondrial alterations observed in DA1-3b/M2 cells were also
found in additional imatinib-resistant leukemic cell lines as well as
in samples from imatinib-resistant patients in blast crises.
Influence of energy substrates on mitochondrial function
in imatinib-resistant leukemic cells
One possible explanation for mitochondrial dysfunction in
imatinib-resistant cells is that metabolic flux of pyruvate is
rerouted through LDH reducing mitochondrial oxidation of
pyruvate thus decreasing mitochondrial respiration. Dichloroace-
tate (DCA), an inhibitor of PDK, increases flux of pyruvate into
mitochondria [32]. As expected from this effect, lactate levels in
the culture medium of the DCA-treated cells decreased (Fig. 4A).
In parallel, activating mitochondria by DCA increased oxygen
consumption in both cell lines until saturation occurred (Fig. 4B).
Notably, DCA-induced mitochondrial activation was less pro-
nounced in DA1-3b/M2 even at saturable doses suggesting that
ETC defects persist in DA1-3b/M2 mitochondria when oxidative
phosphorylation is forced. Consistent with this result, treatment of
DA1-3b/M2 cells with DCA was unable to restore the expression
of ETC complexes (not shown).
One hallmark of high dividing cells is a glucose-induced
repression of oxidative metabolism decreasing mitochondrial
respiration [31]. To get insight into this possibility, we assessed
the impact of glucose deprivation on mitochondrial respiration in
DA1-3b/M2 cells (Fig. 4C). Compared to cells cultured in glucose
medium, respiration rates were increased in galactose-grown DA1-
3b/M2 cells and in cells incubated with 2-DG. As predicted by the
aforementioned results, these culture conditions stimulated the
expression of ETC proteins (Fig. 4D).
Mitochondrial ROS production in imatinib-sensitive and
imatinib-resistant leukemic cells
Transformation of cells by Bcr-Abl increases ROS production
[33]. We considered the possibility that imatinib-resistant could
exhibit higher level of ROS. We subsequently tested the steady-
state levels of mitochondrial ROS in imatinib-resistant cells by
measuring oxidation of the MitoSox Red (Fig. 5A and Fig. S3).
Mitochondrial ROS were higher in DA1-3b/M2 than in DA1-3b
cells and this increase was efficiently blocked by incubation with
the thiol containing antioxidant N-acetyl cystein (NAC). As shown
Figure 3. Impairment of the mitochondrial electron chain complex activity in imatinib resistant cells. (A) Traces of oxygen consumption
of digitonin-permeabilized DA1-3b vs. DA1-3b/M2 cells (left), and K562 vs. K562-IM, K562-NI cells (right). Respiration in response to complex I
(glutamate+malate, 5 mM each) or complex II (succinate, 5 mM) substrates was determined in the presence or absence of 1 mM ADP. Mitochondrial
substrates, N,N,N9,N9-tetramethyl p-phenylenediamine (TMPD 0.5 mM) + ascorbate (1 mM) and respiratory inhibitors, rotenone (2 mM), antimycin A
(1 mM) and potassium cyanide (KCN, 100 mM) were used as indicated: As expected, KCN used as control, blocked mitochondrial respiration. Values for
oxygen consumption are represented on the curves as nmol oxygen/min; One representative experiment of five performed (B–E) Mitochondrial
respiratory chain complex activities (left axes) and protein expression levels of complexes (right axes) in mitochondria isolated from DA1-3b and DA1-
3b/M2 cells. (B) NADH ubiquinone reductase (Complex I), (C) Succinate cytochrome c reductase (Complex II+III), (D) Ubiquinone cytochrome c
reductase (Complex III) and (E) cytochrome c oxidase (Complex IV activity) activities were measured by spectrophotometry as described in Material
and Methods. Rotenone, antimycin A and sodium azide, (prototypic inhibitors of complex activities) were used as control. Quantitative densitometric
analysis of mitochondrial repiratory chain proteins was evaluated on Western blot as depicted in (F). The results are expressed as a ratio of actin
density following reprobing of the membrane. Results are representative of three independent experiments. (*P,0.05 between DA1-3b and DA1-3b/
M2 cells); (F) Western blot analysis of mitochondrial respiratory chain complex proteins such as complex I (20 kDa subunit), complex II (SDHB), III (core
2 protein), IV (Cox II) and V (F1a ATPase). Protein expression patterns were assessed in DA1-3b and DA1-3b/M2 cells, in human K562 (sensitive to
imatinib), K562-NI (resistant to nilotinib and imatinib) and K562-IM (resistant to imatinib) CML cell lines, in normal CD34+ cells (2 separate specimen)
and in cells isolated from four CML patients. BCR-ABL (+) CML cells were isolated from 4 patients: one patient with primary resistance to imatinib
(patient 1), two patients with secondary resistance to imatinib in accelerated/blastic phase (patients 3 and 4) of the disease and one patient (Patient
2) had only a partial response.
doi:10.1371/journal.pone.0021924.g003
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radicals, stimulated the formation of ROS more efficiently in
DA1-3b/M2 than in DA1-3b cells. The same results were
obtained in human imatinib-resistant K562 cells (Fig. S3A) and
when we used the superoxide sensitive fluorochrome Hydroethy-
dine instead of MitoSox (not shown). As assessed by H-NMR,
glutathione, the major component of cellular antioxidant barrier,
was significantly lowered by 30% in DA1-3b/M2 cells relative to
DA1-3b cells (21.8+/21.9 vs. 30.8+/23.4 p,0.001). Since it has
been shown that ROS can be produced by activation of NADPH
oxidase in Bcr-Abl expressing cells [14], we determined NADPH
oxidase activity in the membrane of leukemic cells (Fig. 5B, right).
In both cell lines, NADPH oxidase activity was present in the
membrane fractions and was almost completely prevented by DPI,
a specific inhibitor of flavoproteins. However, no difference in
NADPH oxidase activity between imatinib-sensitive and -resistant
cells was observed. Thus, unlike mitochondria, NADPH oxidase
was not the major source of the increased ROS production
observed in imatinib-resistant cells.
We assumed that mitochondrial alterations are likely to enhance
ROS production. To test this hypothesis, we incubated DA1-3b
cells with various mitochondrial respiration inhibitors before
MitoSox Red staining (Fig. 5C). Interference with any complex
of the electron transport chain led to ROS production that was
prevented by pre-treatment of cells with NAC. In accord with this
result, restoration of an intact ETC in DA1-3b/M2 cells after
treatment with 2-DG or galactose (Fig. 4B) completely abolished
the generation of ROS (Fig. 5D). Conversely, activation of
mitochondria with persistent ETC defects by DCA significantly
increased the level of ROS in DA1/3b-M2 cells. This underscores
the strict correlation between mitochondrial dysfunction and ROS
production indicating that the partial failure of ETC can be
responsible for the excess of mitochondrial ROS in DA1-3b/M2
cells.
Exploiting mitochondrial oxidative stress to kill imatinib-
resistant cells
We next tested if these mitochondrial alterations leading to
ROS production could be therapeutically exploited to preferen-
tially kill imatinib-resistant leukemic cells. As other imatinib-
resistant cells [16], DA1-3b/M2, K562-IM, K562-NI cells
produced more ROS when exposed to the pro-oxidants PEITC
and arsenic trioxide (Trisenox
TM) than their sensitive counterparts
(Fig. 6A and Fig. S3B). Imatinib-resistant cells were more prone to
PEITC or Trisenox-induced apoptosis than imatinib sensitive cells
as revealed by FACS analysis after Annexin V/PI staining (Fig. 6B
and Fig. S3C). Pre-treatment of cells with NAC markedly reduced
Figure 4. Regulation of mitochondrial dysfunction in imatinib
resistant cells. (A) Effect of dichloroactetate (DCA) on lactate
production. DA1-3b and DA1-3b/M2 cells were incubated in the
presence of 6 mM DCA then at the indicated time points, lactate
production was determined. Values are means of two independent
experiments in triplicates; (B) The oxygen consumption was measured
as described in Materials and Methods following the sequential addition
of DCA (1.5 mM every 2 min, arrows) in DA1-3b and DA1-3b/M2 cells.
Typical result out of two independent experiments; (C) Whole-cell
oxygen consumption measurements in DA1-3b/M2 cells treated with
10 mM 2-DG for 18 h or grown in galactose DMEM medium for 48 h
relative to untreated cells (Control, Co.). Data are means +/2 SD of four
independent experiments in duplicate; * indicates p,0.05 compared to
control (D) Typical western blot analysis of mitochondrial respiratory
chain complex proteins in DA1-3b/M2 cells treated as in (C). Actin was
used as a loading control. Data are representative of three independent
experiments.
doi:10.1371/journal.pone.0021924.g004
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generation of ROS (Fig. 6B and Fig. S3C) suggesting that
increased ROS levels are responsible for the pro-apoptotic effects
of PEITC and Trisenox in imatinib-resistant cells. Interestingly,
both ROS production and cell death induced by pro-oxidants
were reduced in DA1-3b/M2 cells when HIF-1a was knocked
down (Fig. 6C).
To verify the relevance of the results in vivo, we investigated the
antitumor effects of PEITC and Trisenox in a syngeneic leukemic
model where injections of small GFP-tagged DA1-3b/M2 cell
numbers led to an aggressive acute leukemia. Mice treated with
PEITC or Trisenox lived significantly longer than untreated mice
(Fig. 6D) in correlation with the lower percentage of GFP+ cells in
spleen (Fig. 6E). To determine whether the antitumor effect was
related to ROS production, analysis of spleen tissues following in
vivo treatments showed that GFP+ cells produced higher levels of
ROS compared to GFP cells, a situation similar to that observed
after ex vivo menadione exposure (Fig. 6F).
Discussion
Cumulative evidence suggests that alterations in glucose
metabolism are associated with Bcr-Abl [7,12,34,35]. These
alterations include increased rates of cytosolic glycolysis along
with reduction in the pentose phosphate cycle activity [35]. Our
findings are compatible with the observation that Bcr-Abl positive
cells greatly depend on glycolysis to supply ATP for proliferation
[34]. We also found a modest but significant induction of genes
encoding for glucose transporters and glycolytic enzymes in
imatinib-resistant leukemic cells. Most of these genes are known to
be under the control of HIF-1a [36], which has been found
abnormally stabilized in imatinib-resistant leukemic cells ([35] and
Fig. 1D). These data suggest that the coordinated induction of
genes by HIF-1a may account for a part of the reprogramming of
glucose from oxidation to glycolysis in imatimib-resistant leukemic
cells.
Figure 5. Mitochondrial ROS production in imatinib- sensitive
and -resistant cell lines. (A) Cytofluorometric analysis of mitochon-
drial ROS production in DA1-3b and DA1-3b/M2. Cells were kept
untreated (Control) or treated with the mitochondrial redox cycling
promoter menadione (100 mm, 1 h) used as positive control then
labeled with the fluorescent probe MitoSox as described in Materials
and Methods. Alternatively, cells were treated with menadione in the
presence of 10 mM NAC (inset). Data represent typical results of one
out of three independent experiments; (B) NADPH oxidase activity in
the plasma membrane of DA1-3b and DA1-3b/M2 cells. When indicated,
cells were treated with the flavoprotein inhibitor diphenyleneiodonium
(DPI), used as control. Lucigenin chemiluninescence assay was used as
described in Material and methods. Results are means +/2 SD of two
independent experiments carried out in triplicates; (C) Effects of various
inhibitors of the mitochondrial respiratory chain on ROS production in
DA1-3b cells. Cells were kept untreated (Control) or treated with 1 mM
rotenone (rot, a know inhibitor of mitochondrial electron transport
complex I), 1 mM 2-thenoyltrifluoroacetone (TTFA, a conventional
complex II inhibitor), 1 mM stigmatellin or 1 mM antimycin A (AA, two
specific inhibitors of mitochondrial complex III) in the presence or
absence of 10 mM N-acetyl cystein (NAC) for 18 h then the levels of
ROS were determined by flow cytometry after Mitosox staining.
Inhibitors were used at sub-toxic concentrations which induce
moderate inhibition of cell respiration (around 20%). Data are means
+/2 SD of four independent experiments; * indicate significant
differences from untreated cells at p,0.05 (D) DA1-3b/M2 cells were
incubated in the presence of the indicated doses of DCA for 1 h, or with
10 mM 2-DG for 18 h, or grown in galactose medium for 48 h then the
levels of ROS were determined by flow cytometry after Mitosox
staining. Data are means +/2 SD of four independent experiments.
* indicate p,0.05 compared to control.
doi:10.1371/journal.pone.0021924.g005
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PLoS ONE | www.plosone.org 11 July 2011 | Volume 6 | Issue 7 | e21924In the last century, Otto Warburg formulated the hypothesis
that metabolic modifications resulted from impairment of cancer
cell mitochondria to undergo respiration [37]. Therefore, in
attempting to understand the metabolic organization of imatinib-
resistant cells, we focused our attention on mitochondria. Herein,
we demonstrated that imatinib-resistant leukemic cells are
characterized by mitochondrial alterations. An irreversible injury
to cellular respiration has been proposed to explain the
dependence of tumours on glycolytic energy [37]. Unlike the
originally belief, our results indicate that increased glycolysis is not
the result of an irremediable inability of mitochondria to utilize
oxidative phosphorylation to produce ATP. In our experiments,
glucose withdrawal does not lead to total ATP depletion in Bcr-
Abl positive cells. This is accomplished by a shift from glycolysis to
mitochondrial OXPHOS. In addition to enhanced glycolysis, our
findings are compatible with the fact that the TCA cycle of Bcr-
Abl positive cells could be fed by glutamate.
Besides, this study shows that glucose metabolism can exert a high
degree of control over oxidative phosphorylation (Fig. 7). Use of
25 mM glucose is conformed to requirements reported for most of
leukemic cell cultures but far higher than in vivo levels. Similar to
results with high glucose medium, DA1-3b/M2 mitochondria were
repressed when studied in vitro after incubation with lower glucose
concentrations or recovered ex vivo from injected mice (not shown)
Figure 6. In vitro and in vivo antitumor activity of PEITC and Trisenox in imatinib resistant cells. (A) DA1-3b and DA1-3b/M2 cells were
treated with 1, 3, 5, 10, 15 and 20 mM of the pro-oxidant phenethyl isothiocyanate (PEITC) for 18 h (left) or with 1, 5, 10 and 20 mM of arsenic trioxide
(Trisenox) for 4 h then mitochondrial ROS production was assessed by flow cytometry using MitoSox. When indicated, cells were pre-treated with
10 mM NAC followed by incubation with 20 mM PEITC for 18 h or with 20 mM PEITC for 4 h. MitoSox fluorescence intensity was presented in arbitrary
units (A.U.). Data are means of three independent experiments (SD,10%); (B) DA1-3b and DA1-3b/M2 cells were treated with PEITC for 18 h or
Trisenox for 4 h in the presence or absence of pretreatment with the antioxidant NAC (10 mM for 1 h). Apoptotic cell death was then determined by
flow cytometry after annexin V–FITC and propidium iodide staining. Flow cytometric profiles shown are representative of two replicate experiments;
(C) Effect of loss of HIF-1a expression in DA-13b/M2 cells on ROS production and cell death. DA1-3b/M2 cells were treated with either HIF-1a siRNA or
control non-targeting siRNA. At 24 h post transfection, cells were treated with 20 mM Trisenox for 4 h, 20 mM PEITC for 18 h or 300 mM Menadione for
1 h, then ROS production and cell death were determined by flow cytometry after MitoSox or PI staining, respectively. Results are presented as the
percentage of inhibition of ROS production or cell death in siRNA HIF-1a transfected cells relative to siControl. (D) In vivo therapeutic activity of PEITC
and Trisenox Survival of mice after injection of 1610
6 GFP-tagged DA1-3b/M2 cells. Cumulative survival data were compiled from two separate
experiments and presented by a Kaplan–Meier survival analysis. GFP+ DA1-3b/M2 bearing mice were treated with Trisenox (4 mg/kg ip 5days/week)
or PEITC (50 mg/kg ip 5days/week). Survival of mice treated with Trisenox (n=10) or with PEITC (n=10) in comparison to control animals (n=20) was
significant (P=0.006 and P=0.0008, respectively); (E) Decrease in percentage GFP+ DA1-3b/M2 cells in spleen after Trisenox and PEITC treatment.
Untreated mice, PEITC- or Trisenox- treated mice were killed 37 days after inoculation of GFP+ DA1-3b/M2 cells. The percentage of GFP+ cells in
spleen was evaluated by flow cytometry. Data are means +/2 SD of three independent experiments; (F) Mitochondrial ROS levels in GFP-tagged DA1-
3b/M2 cells after Trisenox and PEITC treatment in vivo. Untreated mice, PEITC- or Trisenox- treated mice were killed 37 days after inoculation of GFP+
DA1-3b/M2 cells. Spleen cells were stained with MitoSox to determine relative levels of ROS. The experiment was performed twice. Results are fold
change in Mitosox fluorescence intensity of GFP
2 and
+ spleen cells. The values for untreated cells were normalized to 1 for the analysis. As control,
cells were treated with 100 mM menadione for 1 h in vitro.
doi:10.1371/journal.pone.0021924.g006
Figure 7. Suggested sequence of metabolic alterations leading to cell death in imatinib-resistant cells. Imatinib-resistant cells
presented high glycolytic activity controlling mitochondrial oxidative phosphorylation. As a result, mitochondrial dysfunction generated more ROS
spontaneously and after treatment with the pro-oxidants PEITC and Trisenox enhancing cell death sensitivity. Metabolic organization in imatinib-
resistant cells is under control of HIF-1a (see text for details).
doi:10.1371/journal.pone.0021924.g007
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merely a cell culture artefact. As pointed out by Sattler [13,33],
mitochondrial ROS are overproduced in Bcr-Abl positive cells. Our
observations provide mechanistic insights to previous studies
indicating suppression of glycolysis with 2-DG inhibited mitochon-
drial ROS generation [13]. The prevailing hypothesis raised to
explain this effect on mitochondria was that high glycolysis leads to
increased pyruvate oxidation that would stimulate mitochondrial
respiratory chain and ROS overproduction as an unavailable by-
product of increased electron transfer. According to this hypothesis,
impairment of glucose metabolism (with 2-DG or galactose) would
reduce pyruvate oxidation in mitochondria, thereby decreases
mitochondrial respiration and ROS production. Although this has
been examined in a number of cell types [38], we provide evidence
that an alternative mechanism may apply in imatinib-resistant
leukemic cells (Fig. 7). Indeed, we observed that inhibition of
glycolysis causes derepression of respiration and that the subsequent
increase in mitochondrial oxygen consumption limits intracellular
oxygen leading to lower cellular ROS.
In tumours, entry of pyruvate into the TCA cycle is reduced by
inhibition of pyruvate dehydrogenase (PDH) by pyruvate dehy-
drogenase kinase (PDK). Inhibition of PDH decreases mitochon-
drial ETC activity thereby diminishing ROS generation [39]. In
imatinib-resistant cells, we observed a concomitant increase in
PDK3 and a decrease in PDH shunting the pyruvate away from
mitochondria, thereby resulting in the attenuation of mitochon-
drial respiration. Inhibition of PDK with DCA boosts mitochon-
drial activity and ROS generation in imatinib-sensitive and -
resistant cells. However, the effect of DCA was significantly
reduced in DA1-3/M2 cells suggesting that DCA cannot
completely restore the activity of mitochondria in DA1-3b/M2
cells. Nevertheless, administration of DCA may constitute an
alternative strategy to induce ROS-mediated apoptosis in Bcr-Abl
positive cells. Irrespective of these considerations, impairment of
mitochondrial function in imatinib-resistant cells results in
accumulation of the TCA intermediates, succinate and fumarate.
Accumulation of succinate and fumarate in cancer cells induces
inhibition of HIF prolyl hydroxylases allowing the nuclear
translocation of HIF-1a [40]. Therefore, our results suggest that
the TCA cycle inhibition observed in imatinib-resistant cells may
participate to the abnormal stabilization of HIF-1a [35].
In this report, we describe an association between mitochondrial
dysfunction and imatinib resistance in various Bcr-abl expressing
cell lines and in some CML patients with accelerated phase of
CML. These results call for further investigation in additional
patients to determine the exact association and the mechanism of
mitochondrial dysfunction in imatinib resistance. Nevertheless,
these mitochondrial alterations were most probably not due to
BCR-ABL mutations since they are present in both non mutated
(K562-IM, K562-NI [19,20]) and mutated (DA13b/M2) imatinib-
resistant cells. Why imatinib resistant cells adopt this metabolic
profile? Glycolysis is essential for most transformed cells [41]
providing an important growth advantage. Recent work showed
that high glycolysis plays a key role in resistance to imatinib via
p53 inactivation [42]. Additionally, mitochondrial dysfunction
may also play a role in imatinib resistance via the production of
mitochondrial ROS (Fig. 7). Indeed, it is noteworthy that oxidant
stress participates to genomic instability of cancer cells by inducing
oxidative DNA damage. In CML, ROS generation provokes
mutations in kinases domain of Bcr-Abl contributing to emergence
of resistant cells [43].
Finally, we show that these mitochondrial alterations leading to
ROS overproduction can be exploited therapeutically to kill
imatinib-resistant leukemic cells. Treatment strategies that focus
on mitochondrial ROS production represent important opportu-
nities against Bcr-Abl (+) cells [15,44]. Herein, we demonstrated
that the ROS-generating agents, PEITC or arsenic trioxide
selectively killed imatinib-resistant cells through mitochondrial
ROS-mediated damages. Overall, our results support the
hypothesis that a coherent comprehension of the metabolic
organization represents a new paradigm helpful to develop
therapeutic strategies selectively designed to overcome imatinib
resistance.
Supporting Information
Figure S1 The human imatinib resistant cell lines,
K562-IM and K562-NI, express high levels of glycolytic
enzymes. (A) Quantitative PCR analysis of relative transcript
levels of glycolytic enzymes and enzymes related to lactate
metabolism in K562-IM and K562-NI cells compared with
K562 cells. Data are means +/2 SD of three independent
experiments; (B) Western blots analysis and quantification of
several glycolytic-related proteins in total lysates of K562 and
K562-IM, K562-NI cells. Actin protein amounts are used to check
equal loading of proteins. Four independent immunoblottings
were scanned on a densitometer and the expression of proteins in
K562-IM or K562-NI was determined relative to expression in
K562 after normalization with actin. The mean intensity of the
values obtained was expressed in arbitrary units.
(TIF)
Figure S2 Evidence of mitochondrial dysfunction in the
human imatinib resistant cell lines, K562-IM and K562-
NI. (A) Flow cytometric determination of DYm using JC-1
staining. Results are expressed as in Figure 2C. Data are means+/
2 SD of three independent experiments made in duplicates; (B)
Representative oxygen consumption tracings of K562, K562-IM
and K562-NI cells. When compared to the human imatinib-
sensitive cell line K562, K562-IM or K562-NI cells demonstrated
a pronounced reduction in respiration. Data are representative of
three independent experiments; (C) Proportions of mitochondrial
oxygen consumption due to proton leak and ATP turnover in
K562, K562-IM and K562-NI cells.
(TIF)
Figure S3 PEITC and Trisenox induce overproduction
of mitochondrial ROS and subsequent cell death in the
human imatinib resistant cell lines, K562-IM and K562-
NI. (A) Cytofluorometric analysis of mitochondrial ROS produc-
tion in K562, K562-IM and K562-NI cells kept untreated or
incubated with menadione (100 mM, 1 h) in the presence or
absence of 10 mM NAC. MitoSox fluorescence intensity was
presented in arbitrary units (A.U.) Data are means of 3
independent experiments; (B) Cytofluorometric analysis of mito-
chondrial ROS production in K562, K562-IM and K562-NI cells
treated with the indicated doses of PEITC or Trisenox. MitoSox
fluorescence intensity was presented in arbitrary units (A.U.). Data
are means of 2 independent experiments; (C) Flow cytometric
profiles of PEITC (50 mM for 18 h) and Trisenox (20 mM for
18 h)-induced apoptosis in K562, K562-IM and K562-NI cells
using Annexin V-FITC and PI staining. NAC (10 mM) was used
to confirm the role of ROS in PEITC- and Trisenox-induced cell
death. Data are representative of three independent experiments.
(TIF)
Table S1 Characteristics of imatinib-resistant CML
patients included in this study.
(DOC)
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